Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is an orally administered, direct-acting P2Y$_{12}$ receptor antagonist that is reversible. It is used to prevent thrombotic events.
## Primary Indications
* Reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with Acute Coronary Syndrome (ACS) or a history of Myocardial Infarction (MI).
* In combination with aspirin, for the prevention of new thrombotic cardiovascular events in patients with a history of MI.
## Adult Dosing
* **ACS:** A 180 mg loading dose should be administered as soon as possible, followed by 90 mg twice daily.
* **Post-MI (at least 1 year after ACS/MI, or with history of MI):** 90 mg twice daily.
* **Duration of treatment:** Typically 12 months, but may be extended in select patients based on risk assessment.
## Pediatric Dosing
* Ticagrelor is **not recommended** in pediatric patients due to a lack of data.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is required in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is required in patients with mild to severe renal impairment.
## Contraindications
* Hypersensitivity to ticagrelor or any component of the formulation.
* Active pathological bleeding.
## Adverse Effects
* **Common:** Dyspnea, bleeding (major, minor, clinically significant non-major), bradycardia, ventricular pauses.
* **Serious:** Major bleeding events, anaphylaxis, severe dyspnea.
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin):** May increase ticagrelor concentrations. Avoid concomitant use.
* **Strong CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease ticagrelor concentrations. Avoid concomitant use.
* **Other Antiplatelets (e.g., clopidogrel, prasugrel) and Anticoagulants (e.g., warfarin, heparin, DOACs):** Increase the risk of bleeding. Use with caution and monitor closely.
* **Proton Pump Inhibitors (PPIs):** Some studies suggest potential for reduced efficacy when co-administered with ticagrelor, particularly omeprazole and esomeprazole. The clinical significance is uncertain, but consider proton pump inhibitors with less CYP2C19 interaction or alternative acid suppression if clinically appropriate.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding, especially during the initial phase of treatment.
* **Heart Rate:** Monitor for bradycardia.
## Clinical Pearls
* Ticagrelor is dosed twice daily, unlike other P2Y$_{12}$ inhibitors.
* The loading dose is crucial for rapid platelet inhibition.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If discontinuation is necessary, consider the risks and benefits and a shorter interval than typically recommended if possible.
* Ticagrelor has not been shown to be inferior to clopidogrel in patients treated with aspirin alone.
* Patients with a history of stroke or transient ischemic attack (TIA) may have an increased risk of fatal intracranial hemorrhage.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and management may vary based on individual patient factors and local protocols.
